Linperlisib
- Generic Name
- Linperlisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H37FN6O5S
- CAS Number
- 1702816-75-8
- Unique Ingredient Identifier
- 05HYK3CV9N
- Indication
用于既往接受过至少两种系统性治疗的复发或难治滤泡性淋巴瘤成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 606
- Registration Number
- NCT06548347
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT06376721
- Locations
- 🇨🇳
Liang Wang, Beijing, Beijing, China
A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06343935
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Target Recruit Count
- 41
- Registration Number
- NCT06224257
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Real World Study of Linperlisib for Lymphoma Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05863871
- Locations
- 🇨🇳
Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital, Tianjin, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-05-29
- Target Recruit Count
- 8
- Registration Number
- NCT05676710
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 4
- Registration Number
- NCT05676697
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT05559008
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.